source
- Agios ends development of tebapivat in low-risk MDS following subpar resultsAgios Pharmaceuticals has said it will stop developing its rare blood disorder drug for certain patients with myelodysplastic syndromes (MDS) due to disappointing Phase 2b data. The biotech’s pyruv…Endpoints · 2mo ago↗ source
- STAT+: Pharmalittle: We’re reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and morePharma updates from the Pharmalot campus via the Pharmalittle newsletterSTAT · 2mo ago↗ source
- STAT+: Allogene CEO David Chang stepping downPfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The Readout